Tumorigenic Role of Podoplanin in Esophageal Squamous-Cell Carcinoma

Rahadiani, Nur; Ikeda, Jun; Makino, Tomoki; Tian, Tian; Qiu, Ying; Mamat, Suhana; Wang, Yi; Doki, Yuichiro; Aozasa, Katsuyuki; Morii, Eiichi

doi:10.1245/s10434-009-0895-5

Cited by 61 publications

(82 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current findings are in agreement with those obtained by Nakayama et al (18), Rahadiani et al (23) and Tong et al (22), which demonstrated a significant correlation between PDPN tumor expression and pathological stage, depth of tumor invasion and lymph node metastasis in esophageal carcinoma.…”

Section: Discussionsupporting

confidence: 94%

“…These findings are in accordance with the results of studies by Kimura et al (19) and Okazawa et al (20), and our previous study (8), which used immunohistochemistry to demonstrate that esophageal tumors express VEGF-C and VEGF-D. In addition, Tanaka et al (21) used RT-qPCR to demonstrate that esophageal cancer cells express VEGF-C, and Tong et al (22) and Rahadiani et al (23) identified PDPN overexpression in esophageal carcinoma.…”

Section: Discussionsupporting

confidence: 91%

“…Tong et al (22) performed immunohistochemical analysis and, using univariate and multivariate analysis, identified that overexpression of PDPN was both a prognostic factor and independent prognostic factor for 5-year disease-free survival. Furthermore, Rahadiani et al (23) demonstrated that PDPN overexpression was a prognostic factor for OS and Table IV. Cox regression analysis of independent factors affecting overall survival.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic value of vascular endothelial growth factor-C and podoplanin mRNA expression in esophageal cancer

et al. 2015

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 94%

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of vascular endothelial growth factor-C and podoplanin mRNA expression in esophageal cancer

et al. 2015

View full text Add to dashboard Cite

“…Podoplanin knockout mice have lymphatic defects associated with diminished lymphatic transport, congenital lymphedema and dilation of lymphatic vessels [29], suggesting that, under physiological conditions, podoplanin plays an important role in regulating peripheral lung cell proliferation and lymphatic vascular development. Apart from head and neck squamous cell carcinoma, particularly in oral cancer [23,30], podoplanin is expressed in carcinoma of the skin [31], lung [32], uterus [33], colon [34], oesophagus [35,36], in mesothelioma [37] in astrocytoma [38,39]. Investigations have shown that podoplanin, the oncofetal protein M2A recognised by the D2-40 antibody and the type I alveolar cell marker hT1ά-2 are identical proteins [25].…”

Section: Introductionmentioning

confidence: 99%

Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations

et al. 2010

View full text Add to dashboard Cite

Cervical lymph node metastases reduce the overall survival of patients with oral squamous cell carcinoma (OSCC) and require a neck dissection. However, elective management of a clinical N0 neck remains a controversial topic, as there are no reliable factors available predicting cervical lymph node metastases. Recent studies suggest an impact of podoplanin expression on metastatic spread to the cervical lymph nodes. Our aim was to investigate the influence of podoplanin expression on prognosis and metastatic lymphatic spread. In our retrospective study, podoplanin expression was examined in a set of 80 patients with OSCC by immunohistochemistry. We analysed associations between the level of podoplanin expression and various clinicopathologic parameters. In 67 patients (84%), podoplanin was expressed on the tumour cells. Nineteen patients (24%) showed high levels of expression. The 5-year overall survival (31%) for patients with high levels of podoplanin expression was significantly lower (p < 0.001) than for patients with low and moderate expression of podoplanin (93% and 65%, respectively). There was an association between podoplanin expression and the frequency of cervical lymph node metastases. Cervical lymph node metastases were found in 79% of the patients with high podoplanin expression, while patients with weak podoplanin expression had metastases in only 22% (p < 0.001). None of the 13 patients without podoplanin expression had cervical lymph node metastases. We concluded that podoplanin is expressed frequently in OSCC and that podoplanin expression correlates with cervical lymph node metastases and clinical outcome.

show abstract

“…Podoplanin known as D2-40 is a mucin-type transmembrane glycoprotein and a specific marker for lymphatic endothelium. Podoplanin is a candidate CSC marker for human squamous cell carcinoma because the knockdown of podoplanin expression results in vulnerability to anticancer drugs, defective invasion and tumorigenic activity (8)(9)(10). It has been reported that a high level of podoplanin expression correlates with a poor prognosis in oral and esophageal cancer (11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy

Saigusa¹

2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. Neoadjuvant chemo-radiotherapy (CRT) followed by surgery are the standard approaches for locally advanced esophageal cancer. However, the overall cure rate is very low. The aim of this preliminary study was to evaluate the expression of podoplanin and SOX2 known as stemness markers for esophageal squamous cell carcinoma (ESCC) and their association with clinical outcome. We obtained a total of 20 specimens from patients with ESCC who underwent neoadjuvant CRT (30-40 Gy; 5-fluorouracil plus cisplatin) followed by surgery. Podoplanin and SOX2 expression was evaluated using immunohistochemistry and the association of their expressions with clinicopathological variables was investigated. Podoplanin and SOX2 staining was detected not only in residual cancer cells, but also in the basal layer of adjacent normal mucosa after neoadjuvant CRT. High expression of podoplanin was correlated with lymph node metastasis, advanced postoperative stage and vascular invasion (P<0.05), while, high expression of SOX2 was correlated with lymphatic, vascular invasion, poor differentiated tumor and incomplete resection (P<0.05). High expression of podoplanin was significantly associated with poor overall survival (P<0.05). In conclusion, the expression levels of podoplanin and SOX2 expression may be useful prognostic markers for ESCC treated with neoadjuvant CRT.

show abstract

Tumorigenic Role of Podoplanin in Esophageal Squamous-Cell Carcinoma

Abstract: There is a role for podoplanin in tumorigenesis and malignant progression in ESCC.

Cited by 61 publications

References 29 publications

Prognostic value of vascular endothelial growth factor-C and podoplanin mRNA expression in esophageal cancer

Prognostic value of vascular endothelial growth factor-C and podoplanin mRNA expression in esophageal cancer

Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations

Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy

Contact Info

Product

Resources

About